On July 8, 2019 Coherus BioSciences, Inc. ("Coherus" or "the Company", Nasdaq: CHRS), reported that UDENYCA preliminary unaudited net sales for the quarter that ended June 30, 2019 are expected to be in the range of $79.0 million to $84.0 million Coherus BioSciences, Inc. ("Coherus" or "the Company", Nasdaq: CHRS), reported that UDENYCA preliminary unaudited net sales for the quarter that ended June 30, 2019 are expected to be in the range of $79.0 million to $84.0 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Coherus will not disclose topline gross sales, discounts, or gross-to-net data until these data are reported in its Form 10-Q for the quarter ended June 30, 2019.

As announced, Coherus will provide additional financial updates and business highlights on August 1, 2019 at 4:30 p.m. Eastern Time.

.

Coherus will not disclose topline gross sales, discounts, or gross-to-net data until these data are reported in its Form 10-Q for the quarter ended June 30, 2019.

As announced, Coherus will provide additional financial updates and business highlights on August 1, 2019 at 4:30 p.m. Eastern Time.